home / stock / pstv / pstv news

PSTV News and Press, PLUS THERAPEUTICS Inc. From 07/27/23

Stock Information
Company Name: PLUS THERAPEUTICS Inc.
Stock Symbol: PSTV
Market: NYSE
Website: plustherapeutics.com
Menu
PSTV PSTV Quote PSTV Short PSTV News PSTV Articles PSTV Message Board
Get PSTV Alerts

News, Short Squeeze, Breakout and More Instantly...
PSTV - Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations

AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...
PSTV - Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference

AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...

PSTV - Applied DNA, 60 Degrees top healthcare gainers; First Wave, Cadrenal among losers

2023-07-13 10:09:11 ET Gainers: Applied DNA Sciences ( APDN ) +29% . 60 Degrees Pharmaceuticals ( SXTP ) +21% .  Exicure ( XCUR ) +13% . Psychemedics ( PMD ) +11% . Plus Therapeutics ( PSTV ) +9% . Losers: First W...

PSTV - Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...
PSTV - Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT(TM) Clinical Trials at SNMMI Annual Meeting

ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A leptomeningeal metastases trial demonstrates safety and high absorbed radiation doses to the cerebrospinal fluid and leptomeni...

PSTV - Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced t...

PSTV - Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

AUSTIN, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...
PSTV - Plus Therapeutics Provides Company Update Today

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced t...

PSTV - Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023

Plus Therapeutics’ partnership with Medidata resulted in a valid historical control arm for the Company’s Phase 1/2 clinical and potential Phase 3 trials evaluating rhenium ( 186 Re) obisbemeda in recurrent glioblastoma (rGBM) 799 control rGBM patients treated ...

PSTV - Plus Therapeutics to Present at the 2023 Virtual June Investor Summit

AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced to...
Previous 10 Next 10